1 / 67

When, how and which patient to treat with HBV infection.

When, how and which patient to treat with HBV infection. David Mutimer Queen Elizabeth Hospital Birmingham, England. BSG Post-graduate Course March 20 th 2006. WHO Global Burden of Disease 2000 Cirrhosis (all causes). 785,000 deaths per annum from liver failure (cirrhosis, all causes)

pascale-cole
Télécharger la présentation

When, how and which patient to treat with HBV infection.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. When, how and which patient to treat with HBV infection. David Mutimer Queen Elizabeth Hospital Birmingham, England. BSG Post-graduate Course March 20th 2006.

  2. WHO Global Burden of Disease 2000Cirrhosis (all causes) • 785,000 deaths per annum from liver failure (cirrhosis, all causes) • HBV 40% • HCV 25% • Other causes 35% • 600,000 deaths per annum from HCC • HBV 57% • HCV18% • Other causes 25%

  3. WHO Global Burden of Disease 2000Mortality from HBV & HCV • 1 million deaths per annum • including deaths from cirrhosis and/or liver cancer • HBV causes 644,000 deaths per annum • HCV causes 325,000 deaths per annum

  4. = who? When , how and which patient to treat with HBV infection. David Mutimer Queen Elizabeth Hospital Birmingham, England. BSG Post-graduate Course March 20th 2006.

  5. Where do carriers come from?

  6. Where do carriers come from? Acute infection <5% risk Chronic infection “carrier”

  7. Transmission of HBV in England & WalesHahné et al J Clin Virol 2004;29:211-220. Acute HBV infection n=2,876 Resolution & immunity n=2,660 Chronic infection n=216

  8. Transmission of HBV in England & WalesHahné et al J Clin Virol 2004;29:211-220.

  9. Transmission of HBV in England & WalesHahné et al J Clin Virol 2004;29:211-220. New chronic infections in England & Wales (per annum) • Arising in E & W • n = 216 (3%) • Coming from abroad • n = 6,571 (97%)

  10. Where do carriers come from? “carrier” from abroad Acute infection <5% risk Chronic infection “carrier”

  11. Where do carriers come from? “carrier” from abroad Acute infection <5% risk Chronic infection “carrier”

  12. HBV Notifications in England & Wales

  13. HBV Notifications in England & Wales (1990 to 2003)

  14. HIGH-LEVEL REPLICATION HBeAg+ve LOW-LEVEL REPLICATION 40 50 0 20

  15. HIGH-LEVEL REPLICATION HBeAg+ve HBeAg-ve LOW-LEVEL REPLICATION 40 50 0 20

  16. HIGH-LEVEL REPLICATION HBeAg+ve HBeAg-ve LOW-LEVEL REPLICATION 40 50 0 20

  17. HIGH-LEVEL REPLICATION HBeAg+ve HBeAg-ve LOW-LEVEL REPLICATION 40 50 0 20

  18. HIGH-LEVEL REPLICATION HBeAg+ve HBeAg-ve LOW-LEVEL REPLICATION 40 50 0 20

  19. HIGH-LEVEL REPLICATION HBeAg+ve HBV DEATH HBeAg-ve LOW-LEVEL REPLICATION 40 50 0 20

  20. Liver Transplantation for Chronic HBVUK Transplant data : 1990-2003 Male:female 297:47 (6:1) Median age 50

  21. = who? When , how and which patient to treat with HBV infection. David Mutimer Queen Elizabeth Hospital Birmingham, England. BSG Post-graduate Course March 20th 2006.

  22. When , how and which patient to treat with HBV infection. David Mutimer Queen Elizabeth Hospital Birmingham, England. BSG Post-graduate Course March 20th 2006.

  23. HIGH-LEVEL REPLICATION HBeAg+ve • Aim of Treatment • HBeAg seroconversion • Choice of treatment • Interferon • Lamivudine • Adefovir • But! • High rate of spontaneous seroconversion • Little increase with treatment • A lot of females! 40 50 0 20

  24. HIGH-LEVEL REPLICATION HBeAg+ve • Aim of Treatment • HBeAg seroconversion • Choice of treatment • Interferon • Lamivudine • Adefovir • But! • High rate of spontaneous seroconversion • Little increase with treatment • A lot of females! 40 50 0 20

  25. HIGH-LEVEL REPLICATION HBeAg+ve • Aim of Treatment • HBeAg seroconversion • Choice of treatment • Interferon • Lamivudine • Adefovir • But! • High rate of spontaneous seroconversion • Little increase with treatment • A lot of females! 40 50 0 20

  26. Spontaneous HBeAg SeroconversionItalian children Bortolotti et al J Hep 1998 168 HBeAg +ve Median age 5 at entry

  27. Spontaneous HBeAg SeroconversionItalian children Bortolotti et al J Hep 1998 168 HBeAg +ve Median age 5 at entry HBeAg seroconversion @ 8% per annum

  28. Case 1 • 20 year old Asian lady • HBeAg-positive • ALT 50, other LFT’s normal • ? liver biopsy

  29. Case 1 • 20 year old Asian lady • HBeAg-positive • ALT 50, other LFT’s normal • ? liver biopsy – I wouldn’t

  30. Case 1 • 20 year old Asian lady • HBeAg-positive • ALT 50, other LFT’s normal • ? liver biopsy – I wouldn’t • ? antiviral treatment

  31. Case 1 • 20 year old Asian lady • HBeAg-positive • ALT 50, other LFT’s normal • ? liver biopsy – I wouldn’t • ? antiviral treatment – I wouldn’t

  32. Case 1 • 20 year old Asian lady • HBeAg-positive • ALT 50, other LFT’s normal • ? liver biopsy – I wouldn’t • ? antiviral treatment – I wouldn’t • what happened next?

  33. Case 1 • 20 year old Asian lady • HBeAg-positive • ALT 50, other LFT’s normal • ? liver biopsy – I wouldn’t • ? antiviral treatment – I wouldn’t • what happened next? • annual review • spontaneous HBeAg seroconversion 2 years later

  34. HIGH-LEVEL REPLICATION HBeAg+ve • Replication after 40 • Death wish • Always treat! • Aim of treatment • HBV suppression • (HBeAg seroconversion) • Choice of treatment • Lamivudine • Adefovir • (Interferon) HBV DEATH HBeAg-ve 40 50 0 20

  35. HIGH-LEVEL REPLICATION HBeAg+ve • Replication after 40 • Death wish • Always treat! • Aim of treatment • HBV suppression • (HBeAg seroconversion) • Choice of treatment • Lamivudine • Adefovir • (Interferon) HBV DEATH HBeAg-ve 40 50 0 20

  36. HIGH-LEVEL REPLICATION HBeAg+ve • Replication after 40 • Death wish • Always treat! • Aim of treatment • HBV suppression • (HBeAg seroconversion) • Choice of treatment • Lamivudine • Adefovir • (Interferon) HBV DEATH HBeAg-ve 40 50 0 20

  37. Case 2 • 47 year old Chinese male • HBeAg-negative • ALT 55 • what else?

  38. Case 2 • 47 year old Chinese male • HBeAg-negative • ALT 55 • what else? • HBV DNA 500,000 copies/ml • US heterogeneous liver • liver biopsy

  39. Case 2 • 47 year old Chinese male • HBeAg-negative • ALT 55 • what else? • HBV DNA 500,000 copies/ml • US heterogeneous liver • liver biopsy • antiviral treatment?

  40. Case 2 • 47 year old Chinese male • HBeAg-negative • ALT 55 • what else? • HBV DNA 500,000 copies/ml • US heterogeneous liver • liver biopsy • antiviral treatment? • definitely – with nucleosides

  41. HIGH-LEVEL REPLICATION HBeAg+ve HBeAg-ve • Observe? • Further spontaneous selection likely • Females > males • 20’s > 30’s • Reduces costs (indefinite duration of • treatment) • Reduces toxicity (cumulative) • Family planning • Fibrosis is reversible! • Treat? • High risk population • Lowest risk have “self-sorted” • Males > females • 30’s > 20’s • Suppression prevents fibrosis • Indefinite suppression possible! 40 50 0 20

  42. HIGH-LEVEL REPLICATION HBeAg+ve HBeAg-ve • Observe? • Further spontaneous selection likely • Females > males • 20’s > 30’s • Reduces costs (indefinite duration of • treatment) • Reduces toxicity (cumulative) • Family planning • Fibrosis is reversible! • Treat? • High risk population • Lowest risk have “self-sorted” • Males > females • 30’s > 20’s • Suppression prevents fibrosis • Indefinite suppression possible! 40 50 0 20

  43. HIGH-LEVEL REPLICATION HBeAg+ve HBeAg-ve • Observe? • Further spontaneous selection likely • Females > males • 20’s > 30’s • Reduces costs (indefinite duration of • treatment) • Reduces toxicity (cumulative) • Family planning • Fibrosis is reversible! • Treat? • High risk population • Lowest risk have “self-sorted” • Males > females • 30’s > 20’s • Suppression prevents fibrosis • Indefinite suppression possible! 40 50 0 20

  44. HIGH-LEVEL REPLICATION HBeAg+ve HBeAg-ve • Observe? • Further spontaneous selection likely • Females > males • 20’s > 30’s • Fibrosis is reversible? • Reduces costs (indefinite duration of • treatment) • Reduces toxicity (cumulative) • Family planning • Treat? • High risk population • Lowest risk have “self-sorted” • Males > females • 30’s > 20’s • Suppression prevents fibrosis • Indefinite suppression possible? 40 50 0 20

More Related